Login / Signup

Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis.

Mirosława PüsküllüoğluMałgorzata PieniążekAgnieszka RudzińskaAgnieszka PietruszkaRenata Pacholczak-MadejAleksandra Grela-WojewodaMarek Ziobro
Published in: Oncology and therapy (2024)
Due to the hepatotoxicity of BC-active drugs, specific recommendations for systemic treatment are scarce. Our study explored cisplatin's potential use, finding it to be a viable option in patients with performance status 0 or 1 experiencing hepatic IVC/VC, irrespective of liver function parameters and other factors.
Keyphrases
  • public health
  • insulin resistance
  • randomized controlled trial
  • drug induced
  • adipose tissue
  • clinical trial
  • risk assessment
  • open label
  • inferior vena cava
  • young adults
  • skeletal muscle
  • human health
  • study protocol